A month after multi-billion dollar Novartis deal, BeiGene follows up with 'reverse' deal

Just over a month after striking a deal with Novartis to bring its PD-1 antibody tislelizumab stateside, China-based BeiGene is making a similar play in reverse.

On Wednesday evening, BeiGene took the wraps off a $120 million-plus deal with Boston Immune Technologies and Therapeutics to develop and commercialize their tumor necrosis factor receptor 2 (TNFR2) antagonist antibodies in Asia (excluding Japan), Australia and New Zealand.